{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:31:10Z","timestamp":1790742670527,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jpsychires.2022.11.012","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T11:31:24Z","timestamp":1668425484000},"page":"713-721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Impact of cannabis use and its cessation on the dosage and the efficacy of antipsychotic drugs in in- and outpatients with schizophrenia taking medication: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5868-1262","authenticated-orcid":false,"given":"Oph\u00e9lie","family":"Rault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Butlen-Ducuing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Rari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Benyamina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"694394","key":"10.1016\/j.jpsychires.2022.11.012_bib1","article-title":"The impact of THC and CBD in schizophrenia: a systematic review. Front","volume":"12","author":"Ahmed","year":"2021","journal-title":"Psychiatry"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.euroneuro.2020.03.003","article-title":"The impact of sex and cannabis on clinical features in first-admitted patients with psychosis. Eur. Neuropsychopharmacol. J","volume":"36","author":"Arranz","year":"2020","journal-title":"Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.psychres.2019.06.023","article-title":"Association of smoked cannabis with treatment resistance in schizophrenia","volume":"278","author":"Arsalan","year":"2019","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib4","first-page":"729","article-title":"A study of the impact of cannabis on doses of discharge antipsychotic medication in individuals with schizophrenia or schizoaffective disorder. Psychiatr","volume":"87","author":"Babatope","year":"2016","journal-title":"Far E. Q."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","article-title":"In vitro P-glycoprotein affinity for atypical and conventional antipsychotics","volume":"71","author":"Boulton","year":"2002","journal-title":"Life Sci."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib6","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1038\/npp.2017.50","article-title":"The differential binding of antipsychotic drugs to the ABC transporter P-glycoprotein predicts cannabinoid-antipsychotic drug interactions","volume":"42","author":"Brzozowska","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.phrs.2016.01.033","article-title":"Cannabidiol, neuroprotection and neuropsychiatric disorders","volume":"112","author":"Campos","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF00196109","article-title":"Smoking and body weight influence the clearance of chlorpromazine","volume":"46","author":"Chetty","year":"1994","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.neubiorev.2016.03.010","article-title":"Effect of cannabis on glutamate signalling in the brain: a systematic review of human and animal evidence. Neurosci","volume":"64","author":"Colizzi","year":"2016","journal-title":"BioBehav. Rev."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.psychres.2018.08.005","article-title":"Longitudinal assessment of the effect of cannabis use on hospital readmission rates in early psychosis: a 6-year follow-up in an inpatient cohort","volume":"268","author":"Colizzi","year":"2018","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib11","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1038\/s41380-019-0374-8","article-title":"Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis","volume":"25","author":"Colizzi","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.schres.2020.03.071","article-title":"Chronic smoking and cognition in patients with schizophrenia: a meta-analysis","volume":"222","author":"Coustals","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib13","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.biopsych.2013.06.011","article-title":"Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function","volume":"75","author":"Demjaha","year":"2014","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Contr. Clin. Trials"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib15","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/sj.npp.1301643","article-title":"Blunted psychotomimetic and amnestic effects of \u0394-9-tetrahydrocannabinol in frequent users of cannabis","volume":"33","author":"D'Souza","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.schres.2020.09.013","article-title":"Glutamate in schizophrenia: neurodevelopmental perspectives and drug development","volume":"223","author":"Egerton","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib17","article-title":"Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia","author":"Emsley","year":"2019","journal-title":"Schizophr"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib18","first-page":"86","article-title":"Assessment and management of agitation in psychiatry: expert consensus. World J","volume":"17","author":"Garriga","year":"2016","journal-title":"Biol. Psychiatr."},{"issue":"12","key":"10.1016\/j.jpsychires.2022.11.012_bib19","article-title":"Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review","volume":"17","author":"Gillespie","year":"2017","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib20","first-page":"8","article-title":"Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia","volume":"2","author":"Green","year":"2016","journal-title":"J. Clin"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.schres.2003.08.001","article-title":"First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol","volume":"66","author":"Green","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib22","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","article-title":"Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990\u20132017: systematic review and meta-analysis","volume":"191","author":"Hunt","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/15504263.2016.1245457","article-title":"The effects of cannabis on inpatient Agitation, aggression, and length of stay","volume":"12","author":"Johnson","year":"2016","journal-title":"J. Dual Diagn."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib26","first-page":"927","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am","volume":"174","author":"Leucht","year":"2017","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib27","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.pnpbp.2010.11.007","article-title":"Psychopharmacological comparison of schizophrenia spectrum disorder with and without cannabis dependency","volume":"35","author":"Makkos","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.euroneuro.2018.12.003","article-title":"Cannabis induced increase in striatal glutamate associated with loss of functional corticostriatal connectivity","volume":"29","author":"Mason","year":"2019","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2009.04.018","article-title":"A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia","volume":"113","author":"Miller","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib31","year":"2014"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/08039488.2019.1632381","article-title":"Cannabis use correlates with aggressive behavior and long-acting injectable antipsychotic treatment in Asian patients with schizophrenia","volume":"73","author":"Park","year":"2019","journal-title":"Nord. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib34","author":"Patel"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: \u0394 9 -tetrahydrocannabinol, cannabidiol and \u0394 9 -tetrahydrocannabivarin: \u0394 9 -THC, CBD and \u0394 9 -THCV","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib36","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.psychres.2013.08.043","volume":"210","author":"Picci","year":"2013","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2019.112523","article-title":"Antipsychotic treatment failure in patients with psychosis and co-morbid cannabis use: a systematic review","volume":"280","author":"Reid","year":"2019","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.drugpo.2017.11.008","article-title":"Routes of administration for cannabis use \u2013 basic prevalence and related health outcomes: a scoping review and synthesis","volume":"52","author":"Russell","year":"2018","journal-title":"Int. J. Drug Pol."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0269881118760662","article-title":"Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders","volume":"32","author":"Sami","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib40","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1080\/10826080802587298","article-title":"Cannabis using schizophrenia patients treated with atypical neuroleptics: do their symptoms differ from those of cannabis abstainers?","volume":"43","author":"Schaub","year":"2008","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.114022","article-title":"Cannabis use and clinical outcome in people with first-episode schizophrenia spectrum disorders over 24 months of treatment","volume":"302","author":"Scheffler","year":"2021","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib42","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamapsychiatry.2016.2427","article-title":"Association between continued cannabis use and risk of relapse in first-episode psychosis a quasi-experimental investigation within an observational study","volume":"73","author":"Schoeler","year":"2016","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2215-0366(15)00363-6","article-title":"Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis","volume":"3","author":"Schoeler","year":"2016","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib44","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S2215-0366(16)30188-2","article-title":"Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study","volume":"3","author":"Schoeler","year":"2016","journal-title":"Lancet Psychiatr."},{"issue":"769","key":"10.1016\/j.jpsychires.2022.11.012_bib45","article-title":"Risperidone provides better improvement of sleep disturbances than haloperidol therapy in schizophrenia patients with cannabis-positive urinalysis. Front","volume":"9","author":"Thomas-Brown","year":"2018","journal-title":"Pharmacol"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2012.01.016","article-title":"Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study","volume":"137","author":"Van Dijk","year":"2012","journal-title":"Schizophr. Res."},{"issue":"328","key":"10.1016\/j.jpsychires.2022.11.012_bib47","article-title":"Protocol for the management of psychiatric patients with psychomotor agitation","volume":"17","author":"Vieta","year":"2017","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib48","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Vos","year":"2017","journal-title":"Lancet"},{"issue":"135","key":"10.1016\/j.jpsychires.2022.11.012_bib49","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.jpsychires.2022.11.012_bib50","author":"Wells"},{"key":"10.1016\/j.jpsychires.2022.11.012_bib51","article-title":"Evolution of substance use, neurological and psychiatric symptoms in schizophrenia and substance use disorder patients: a 12-week, pilot, case\u2013control trial with quetiapine","author":"Zhornitsky","year":"2011","journal-title":"Front. Times"},{"issue":"833","key":"10.1016\/j.jpsychires.2022.11.012_bib52","article-title":"Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system","volume":"19","author":"Zou","year":"2018","journal-title":"Int. J. Mol. Sci."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395622006367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395622006367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:38:54Z","timestamp":1758368334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395622006367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":52,"alternative-id":["S0022395622006367"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2022.11.012","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of cannabis use and its cessation on the dosage and the efficacy of antipsychotic drugs in in- and outpatients with schizophrenia taking medication: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2022.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}